Immunosuppressants are the gold standard therapy for many renal diseases. However, systemic side effects are major drawbacks. In this project the potential of lipid nanoparticles, functionalized to target kidney integrins and loaded with novel therapeutic substances will be investigated as a potential renal specific therapy. The scientist will use three different zebrafish kidney disease models and characterize the uptake of nanoparticles. Afterwards therapeutic substances including small molecules, gene therapy and immunosuppressive agents will be loaded into the functionalized nanoparticles before injecting them in zebrafish blood circulation. The experiments enable in vivo analysis of nanoparticles as potential cell type specific drug delivery systems in a high throughput fashion. 

Here you can find further information.